Significant Associations Between Well-Known Clinical and Biological Variables on Clinical Response in AML and In Vitro Resistance Variables
| Characteristics (clinical and biological variables) . | Associated With5-150 . | P Value5-151 . |
|---|---|---|
| Older age | High MDR1 expression (RT-PCR) | .01 |
| High Pgp expression (flow cytometry) | .01 | |
| High effect of CsA on calcein-AM uptake | .009 | |
| High LC50 of Ara-C | .04 | |
| High LC50 of DNR | .05 | |
| High WBC at diagnosis | High Mvp/LRP expression (flow cytometry) | .02 |
| Unfavorable cytogenetics | Effect of both CsA and probenecid on calcein-AM uptake | .002 |
| High LC50 of Ara-C | .02 | |
| High LC50 of DNR | .03 |
| Characteristics (clinical and biological variables) . | Associated With5-150 . | P Value5-151 . |
|---|---|---|
| Older age | High MDR1 expression (RT-PCR) | .01 |
| High Pgp expression (flow cytometry) | .01 | |
| High effect of CsA on calcein-AM uptake | .009 | |
| High LC50 of Ara-C | .04 | |
| High LC50 of DNR | .05 | |
| High WBC at diagnosis | High Mvp/LRP expression (flow cytometry) | .02 |
| Unfavorable cytogenetics | Effect of both CsA and probenecid on calcein-AM uptake | .002 |
| High LC50 of Ara-C | .02 | |
| High LC50 of DNR | .03 |
The variables analyzed were: MDR1, MRP1, andMvp/LRP gene expression (measured by RT-PCR and flow cytometry), Pgp function (measured by the effect of CsA on calcein-AM uptake), MRP1 function (measured by the effect of probenecid on calcein-AM uptake), the simultaneous function of both Pgp and MRP1 (measured by the combined effect of CsA and probenecid on calcein-AM uptake), and the in vitro resistance to DNR, etoposide, and Ara-C (measured by the MTT assay).
Only associations with P value ≤.05 on log regression were recorded in the table.